On 15 May 2009, orphan designation (EU/3/09/637) was granted by the European Commission to Wellstat Therapeutics EU Limited, United Kingdom, for 2',3',5'-tri-O-acetyluridine for the treatment of 5-fluorouracil overdose.
Treatment of 5-fluorouracil overdose
|Orphan designation status||
|EU designation number||
|Date of designation||
|September 2023||The sponsorship was transferred from Wellstat Therapeutics EU Limited, Ireland to Serb, France.|
|February 2021||The sponsorship was transferred to Wellstat Therapeutics EU Limited, Ireland.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: